Drug intelligence / Profile preview

6g

Development stage: Preclinical
Lead developer: Zydus Research Centre
Modality: Small Molecules
Administration: Oral

Overview

6g is a novel, potent, and selective small molecule agonist of the G protein-coupled receptor TGR5 (also known as GPR131, GPBAR1, or M-BAR). Activation of TGR5 by 6g promotes the secretion of glucagon-like peptide-1 (GLP-1) and modulates insulin secretion, leading to glucose-lowering effects. It has demonstrated a favorable pharmacokinetic profile and potent glucose-lowering effects in vivo during oral glucose tolerance tests in DIO C57 mice. Developed by Zydus Research Centre, Cadila Healthcare Ltd., 6g is being investigated for the treatment of type 2 diabetes.

Targets

GPBAR1XCR1 (X-C motif chemokine receptor 1)

Beyond the preview

Go deeper on 6g.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6g.

Explore the full profile